These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12529733)

  • 1. Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
    Abrams CS; Cines DB
    Thromb Haemost; 2002 Dec; 88(6):888-9. PubMed ID: 12529733
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
    Brassard JA; Curtis BR; Cooper RA; Ferguson J; Komocsar W; Ehardt M; Kupfer S; Maurath C; Swabb E; Cannon CP; Aster RH
    Thromb Haemost; 2002 Dec; 88(6):892-7. PubMed ID: 12529735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists.
    Stiegler HM; Fischer Y; Steiner S
    Lancet; 1999 Apr; 353(9159):1185. PubMed ID: 10210005
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH;
    J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
    Aster RH
    Chest; 2005 Feb; 127(2 Suppl):53S-59S. PubMed ID: 15706031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW
    Semin Thromb Hemost; 2004 Oct; 30(5):569-77. PubMed ID: 15497099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Abrams CS; Cines DB
    Curr Hematol Rep; 2004 Mar; 3(2):143-7. PubMed ID: 14965491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor.
    Weisman HF; Schaible TF; Jordan RE; Cabot CF; Anderson KM
    Biochem Soc Trans; 1995 Nov; 23(4):1051-7. PubMed ID: 8654680
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
    Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
    Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute severe thrombocytopenia after treatment with ReoPro (abciximab).
    Butler R; Hubner PJ
    Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of recurrent thrombocytopenia due to abciximab.
    Sharma V; Mascarenhas D
    J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816
    [No Abstract]   [Full Text] [Related]  

  • 12. Surgical implications of platelet glycoprotein IIb-IIIa inhibition.
    Duke C; Grammie JS
    J Thorac Cardiovasc Surg; 1998 Dec; 116(6):1083-4. PubMed ID: 9832706
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
    Rasti M; Blostein M
    Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off?
    Jeremias A; Gruberg L
    J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
    Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 19. [Glycoprotein IIb/IIIa receptor inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1996 Dec; 19(12):356-8. PubMed ID: 9082150
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.
    Jeske WP; Walenga JM; Szatkowski E; Ero M; Herbert JM; Haas S; Bakhos M
    Thromb Res; 1997 Nov; 88(3):271-81. PubMed ID: 9526947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.